File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage

TitleAntiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage
Authors
Issue Date2013
PublisherWiley for Cochrane Collaboration. The Journal's web site is located at http://www.wiley.com/WileyCDA/Brand/id-6.html?category=For+Working
Citation
Cochrane Database of Systematic Reviews, 2013, n. 6, article no. CD008710 How to Cite?
AbstractBACKGROUND: Subarachnoid haemorrhage may result in seizures both acutely and in the longer term. The use of antiepileptic drugs (AEDs) in the primary and secondary prevention of seizures after subarachnoid haemorrhage is uncertain, and there is currently no consensus on treatment. OBJECTIVES: To assess the effects of AEDs for the primary and secondary prevention of seizures after subarachnoid haemorrhage. SEARCH METHODS: We searched the Cochrane Epilepsy Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 1) in The Cochrane Library, and MEDLINE (1946 to 12th March 2013). We checked the reference lists of articles retrieved from these searches. SELECTION CRITERIA: We considered all randomised and quasi-randomised controlled trials in which patients were assigned to a treatment (one or more AEDs) or placebo. DATA COLLECTION AND ANALYSIS: Two review authors (RM and JK) independently screened and assessed the methodological quality of the studies. If studies were included, one author extracted the data and the other checked it. MAIN RESULTS: No relevant studies were found. AUTHORS' CONCLUSIONS: There was no evidence to support or refute the use of antiepileptic drugs for the primary or secondary prevention of seizures related to subarachnoid haemorrhage. Well-designed randomised controlled trials are urgently needed to guide clinical practice.
Persistent Identifierhttp://hdl.handle.net/10722/194540
ISSN
2023 Impact Factor: 8.8
2020 SCImago Journal Rankings: 1.319
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMarigold, R-
dc.contributor.authorGunther, A-
dc.contributor.authorTiwari, D-
dc.contributor.authorKwan, SKJ-
dc.date.accessioned2014-02-07T02:23:53Z-
dc.date.available2014-02-07T02:23:53Z-
dc.date.issued2013-
dc.identifier.citationCochrane Database of Systematic Reviews, 2013, n. 6, article no. CD008710-
dc.identifier.issn1469-493X-
dc.identifier.urihttp://hdl.handle.net/10722/194540-
dc.description.abstractBACKGROUND: Subarachnoid haemorrhage may result in seizures both acutely and in the longer term. The use of antiepileptic drugs (AEDs) in the primary and secondary prevention of seizures after subarachnoid haemorrhage is uncertain, and there is currently no consensus on treatment. OBJECTIVES: To assess the effects of AEDs for the primary and secondary prevention of seizures after subarachnoid haemorrhage. SEARCH METHODS: We searched the Cochrane Epilepsy Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 1) in The Cochrane Library, and MEDLINE (1946 to 12th March 2013). We checked the reference lists of articles retrieved from these searches. SELECTION CRITERIA: We considered all randomised and quasi-randomised controlled trials in which patients were assigned to a treatment (one or more AEDs) or placebo. DATA COLLECTION AND ANALYSIS: Two review authors (RM and JK) independently screened and assessed the methodological quality of the studies. If studies were included, one author extracted the data and the other checked it. MAIN RESULTS: No relevant studies were found. AUTHORS' CONCLUSIONS: There was no evidence to support or refute the use of antiepileptic drugs for the primary or secondary prevention of seizures related to subarachnoid haemorrhage. Well-designed randomised controlled trials are urgently needed to guide clinical practice.-
dc.languageeng-
dc.publisherWiley for Cochrane Collaboration. The Journal's web site is located at http://www.wiley.com/WileyCDA/Brand/id-6.html?category=For+Working-
dc.relation.ispartofCochrane Database of Systematic Reviews-
dc.rightsThis Cochrane Review was published in the Cochrane Database of Systematic Reviews 2013, Issue 6. Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Cochrane Review.-
dc.subject.meshAnticonvulsants - therapeutic use-
dc.subject.meshHumans-
dc.subject.meshSecondary Prevention - methods-
dc.subject.meshSeizures - etiology - prevention and control-
dc.subject.meshSubarachnoid Hemorrhage - complications-
dc.titleAntiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhageen_US
dc.typeArticleen_US
dc.identifier.emailKwan, SKJ: jskkwan@hku.hk-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1002/14651858.CD008710.pub2-
dc.identifier.pmid23740537-
dc.identifier.pmcidPMC6885058-
dc.identifier.scopuseid_2-s2.0-84890205829-
dc.identifier.hkuros227906-
dc.identifier.issue6-
dc.identifier.spagearticle no. CD008710-
dc.identifier.epagearticle no. CD008710-
dc.identifier.isiWOS:000321124500038-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1361-6137-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats